News

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights our March Mental Health issue of Contemporary Pediatrics.

Guidance now aligns with isolation recommendations for influenza and other respiratory illnesses.

Walgreens and CVS pharmacies are set to dispense mifepristone in select states, aiming to address legal complexities and enhance accessibility amidst ongoing regulatory and legal battles.

Viaskin milk patch shows promise in cow’s milk allergy, particularly in children aged 2-11 with 300 μg dose, though the other doses examined failed to prove significant benefit.

Across all age groups polled, 49% of parents agreed that using headphones helped keep their child entertained.

Study authors of a paper published in The New England Journal of Medicine highlighting omalizumab for multiple common food allergies provided their comments regarding positive phase 3 data.

Scott Ceresnak, MD, explains smartwatch technology could be a great tool in detecting arrhythmias in children, however, given that algorithms in the technology were designed for adults, caution must be used as well.

"Collaboration can help us make more accurate diagnoses, develop more effective multimodal treatment plans, and monitor progress in many areas," said James Wallace, MD.

A poster presentation at AAAAI from the phase 3 PEOPLE Study revealed DBV712 treatment in children with peanut allergy has a favorable safety and tolerability profile.

A new study found female teens and young adults were more likely to have an increased antidepressant dispensing rate during the pandemic than male peers.

Omalizumab was approved by the FDA on February 16, 2024 as the first and only FDA-approved medicine to reduce allergic reactions in patients with 1 or more food allergies.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Thomas Casale, MD, discusses phase 3 data presented at the 2024 AAAAI Meeting in Washington DC, highlighting neffy's efficacy in pediatric patients at risk for anaphylaxis.

Take this short quiz and test your knowledge of the American Academy of Pediatrics' clinical practice guideline to evaluate and treat children and adolescents with obesity.

Sarina Tanimoto, MD, MBA, breaks down a poster session regarding the pharmacokinetic profile of neffy, presented at the 2024 American Academy of Allergy, Asthma, & Immunology Annual Meeting in Washington DC from February 23 to February 26, 2024.

The Rare Pediatric Disease Designation joins the Fast Track and Orphan Designations that have already been granted to AOC 1044.

A Prescription Drug User Fee Act (PDUFA) target action date of June 21, 2024, has been set by the FDA.

Donna Hallas shares her perspectives on the most recent issue of Contemporary Pediatrics.

ARS Pharma plans to submit data from the repeat dose study of neffy to the FDA early in the second quarter of 2024, as part of its response to the CRL issued by the federal agency for the previously submitted New Drug Application (NDA).

No concerning patterns of long-term or increasing opioid use were observed within 3 years after first opioid prescription in opioid-naive children with SCD.

How effective can wearable technology with features designed for adults be for children when it comes to arrhythmias? Scott Ceresnak, MD, helps provide the answer in this Contemporary Pediatrics interview.

Microalbuminuria and low body iron levels displayed a significant association with pediatric hearing loss independently.

Procalcitonin can be useful for point-of-care testing in patients with influenza-like illness and a prolonged fever, guiding the indication for a chest radiograph while helping to avoid radiation exposure.

Hearing loss was more prevalent among children and adults with sickle cell disease and its traits compared to matched controls with normal hemoglobin.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The approval makes omalizumab the first and only FDA-approved medicine to reduce allergic reactions in patients with one or more food allergies.

The Orphan Drug Designation follows the receipt of Rare Pediatric Disease Designation from the FDA in January 2024.

Lawrence Eichenfield, MD, highlights the sNDA submission of tapinarof cream, 1% for the topical treatment of atopic dermatitis in children aged 2 years and older.

Promoting mental health and implementing stress-reducing scenarios for adolescents could lessen motivating factors for substance use.